RecruitingNot ApplicableNCT07093606
Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
Sponsor
Sohag University
Enrollment
100 participants
Start Date
Jul 14, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Eltrombopag for people with itp - immune thrombocytopenia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEltrombopag
ITP patients will receive Eltrombopag and evulate occurance of liver disordres .
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07093606
Related Trials
OM336 in Autoimmune Cytopenias
NCT070839603 locations
Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia
NCT07788456
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT0719485020 locations
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
NCT0754969810 locations
Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study
NCT071336591 location